(800) 526-OPYS Pay my bill Member login
logo
OPYS 10 years
  • Hospital Solutions
    • Emergency Medicine
    • Hospital Medicine
    • Telemedicine
    • Urgent Care
    • Post Acute Care
    • Correctional Medicine
    • Locum Tenens
  • Join our Team
    • Physicians
    • Advanced Practitioners
    • Career Opportunities
  • About OPYS
    • Experienced Group
    • Metrics & Outcomes
    • Throughout the US
    • Quality Patient Care
    • Clinical Performance
    • Qualified Providers
    • Company Profile
    • Leadership Team
    • Mission Statement
    • Reviews
  • News
  • Contact Us

New Information on the Link Between Maternal Antidepressant Use and Birth Defects

Home > Best Practice > New Information on the Link Between Maternal Antidepressant Use and Birth Defects

New Information on the Link Between Maternal Antidepressant Use and Birth Defects

January 30, 2023

The relationship between maternal antidepressant use and fetal health has long been of concern to both the women’s health and pediatrics communities. Research into how antidepressants affect a growing fetus has led to some actionable information on which antidepressants are safest and if and how certain women can stay on antidepressants while pregnant. However, given the challenges of conducting randomized controlled studies on pregnant women, our understanding of the specific impact of antidepressants on fetal development is limited.

 

New results published in JAMA Psychiatry suggest that some antidepressants may lead to specific birth defects. Based on previous work that has shown that selective serotonin reuptake inhibitors (SSRIs) and venlafaxine may increase the likelihood of birth defects, the authors of this latest study aimed to clarify which specific medications may lead to these types of adverse outcomes.

 

Physicians along with researchers evaluated data from more than 42,000 mothers. More than 30,000 of these mothers had infants who had birth defects. They found that 1,562 of the mothers of those with birth defects – or 5.1% – used antidepressants early in their pregnancy. By comparison, 467 – or 4.1% – of those whose infants did not have birth defects used antidepressants during this part of pregnancy.

 

While both SSRIs and venlafaxine were associated with birth defects, the associations mainly only persisted after underlying conditions were accounted for in the case of venlafaxine. SSRI associations with, for instance, congenital heart defects, were attenuated after controlling for underlying conditions.

 

These results offer new insights into how antidepressants may affect fetal health when taken by pregnant women. However, there is also significant evidence highlighting the risks to the fetus when a pregnant woman is depressed and untreated. More research is therefore needed to help delineate the specific ways that women can maintain both their and their childrens’ health when they suffer from depression during pregnancy.

 

 

 

Reference

 

Anderson, K.N. (2020). Maternal use of specific antidepressant medications during early pregnancy and the risk of selected birth defects. JAMA Psychiatry,  doi:10.1001/jamapsychiatry.2020.2453.

Filed Under: Best Practice, General, Patient Care, Public Health, Women's Health Tagged With: Health care, Medications, Mental Health, OPYS, patient care, Pediatrics

Search

Categories

  • Best Practice
  • Cardiologists
  • COVID-19
  • Emergency Physicians
  • General
  • Health Technology
  • Hospital Physicians
  • Hospitalists
  • New Job Opportunities
  • Nurses
  • Patient Care
  • Physician Job
  • Physician Services News
  • Public Health
  • Reimbursement
  • Telehealth Blog Series
  • Women's Health

Archives

  • February 2023
  • January 2023
  • December 2022
  • November 2022
  • October 2022
  • September 2022
  • April 2022
  • January 2022
  • December 2021
  • November 2021
  • October 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • April 2021
  • March 2021
  • February 2021
  • January 2021
  • December 2020
  • September 2020
  • July 2020
  • June 2020
  • May 2020
  • April 2020
  • March 2020
  • February 2020
  • December 2017
  • March 2017
  • June 2016
  • August 2015
  • December 2011
  • November 2011
  • October 2011
  • September 2011
  • August 2011
  • July 2011
  • June 2011
  • May 2011
  • April 2011
  • March 2011
  • February 2011

We’d Love to Hear From You,
Get In Touch With Us!

logo

Since 2012, providing quality, efficient, patient-centered healthcare through experienced medical leadership, communication, and collaboration in the provision of hospital-based physician outsourcing services.

Our Services
  • Emergency Medicine
  • Hospital Medicine
  • Telemedicine
  • Urgent Care
  • Post Acute Care
  • Correctional Medicine
OPYS Advantage
  • Our Team
  • Investor Relations
  • Career Opportunities
Contact
Corporate Office 

One Indiana Square, Suite 2060
Indianapolis, IN 46204

Phone: (800) 526-6797
Fax: (800) 456-6148
Email: info@opys.com

Copyright © 2012 - 2022. All rights reserved I Site Map I Privacy Policy I Terms and Use